Research and Markets has announced the addition of the "Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2016" report to their offering.
Fibrinogen Deficiency (Factor I Deficiency) pipeline therapeutics constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.
Fibrinogen Deficiency (Factor I Deficiency) Factor I (or fibrinogen) deficiency is a rare inherited bleeding disorder with complications that vary with the severity due to factor I. Factor I deficiency occurs if fibrinogen is missing (Afibrinogenemia) or is present but at a lower level than normal (Hypofibrogenemia), does not function properly (Dysfibrinogenemia) or the clotting reaction is blocked prematurely and the blood clot does not form. Possible treatments include fibrinogen replacement therapy where fibrinogen concentrates are administered to the diseased patient. Plasma and cryoprecipitate are also used for treatment purposes.
The report 'Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews of key players involved in therapeutic development for Fibrinogen Deficiency (Factor I Deficiency) and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III and Phase II stages are 4 and 1 respectively.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/664frd/fibrinogen
View source version on businesswire.com: http://www.businesswire.com/news/home/20161003006246/en/Business Wire
Last updated on: 03/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.